‘Pharma bro’ Martin Shkreli released from federal prison and into New York halfway house

‘Pharma bro’ Martin Shkreli released from federal prison and into New York halfway house


Former pharmaceutical executive Martin Shkreli departs the U.S. District Court for the Eastern District of New York, August 3, 2017 in the Brooklyn borough of New York City.

Getty Images

Notorious “Pharma bro” fraudster Martin Shkreli was released from a federal prison in Pennsylvania on Wednesday and into a U.S. Bureau of Prisons halfway house at an undisclosed location in New York to complete the rest of his criminal sentence, his lawyer said.

In a throwback to the days when Shkreli was one of the most prominent trolls on Twitter, a friend of his tweeted a photo of them together smiling in a car after his release, with the caption: “Picked up this guy hitchhiking. Says he’s famous.”

His friend was wearing a t-shirt featuring a photo of Shkreli smirking during testimony before Congress, with the words, “Free Shkreli” underneath it.

“Getting out of real prison is easier than getting out of Twitter prison,” Shkreli wrote on his Facebook page Wednesday, referring to his ban from Twitter, which dates to his harassment of a female journalist in 2017.

Shkreli, a 39-year-old New York City resident who was convicted of securities fraud in 2017, previously was due to be released from the Allenwood low-security federal correctional institution on Sept. 14.

Shkreli was sentenced to 7 years in prison in March 2018. His release slightly more than four years after that sentencing reflects the credit he received for good behavior in prison, and for completing education and rehabilitation programs while locked up.

It also reflects the fact that Shkreli already had spent nearly six months in jail before he was sentenced. A federal judge revoked his release bond in September 2017, two months after his conviction, after he offered Facebook followers a $5,000 bounty for samples of Hillary Clinton’s hair.

CNBC Politics

Read more of CNBC’s politics coverage:

Shkreli’s lawyer Benjamin Brafman, in a statement Wednesday, said, “I am pleased to report that Martin Shkreli has been released from Allenwood prison and transferred to a BOP halfway house after completing all programs that allowed his prison sentence to be shortened.”

“While in the halfway house I have encouraged Mr. Shkreli to make no further statement, nor will he or I have any additional comments at this time,” Brafman said.

A Bureau of Prisons spokesman said Shkreli was transferred to community confinement overseen by the agency’s Residential Reentry Management Office.  

“Community confinement means the inmate is in either home confinement or a Residential Reentry Center (RRC, or halfway house),” the spokesman said in a statement. “Mr. Shkreli’s projected release date from the custody of the BOP is September 14, 2022. For safety and security reasons, we do not discuss any individual inmate’s conditions of confinement to include transfers or release plans.”

Shkreli gained national infamy in 2015 when his second pharmaceuticals company Vyera summarily raised the price of the lifesaving drug Daraprim by more than 4,000% overnight.

Shkreli earned the sobriquet “Pharma bro” for smugly defending that price increase, for insulting people on Twitter who called out his behavior, and for his purchase of a one-of-a-kind Wu-Tang Clan album for $2 million.

But his criminal conviction is unrelated to the price increase of that anti-parasite medication.

Shkreli was arrested in late 2015 on charges that accused him of defrauding investors at two hedge funds to found his first drug company, Retrophin. He also was charged with looting Retrophin to pay back investors at his hedge funds for losses that he had covered up.

He was convicted at trial in July 2017 in Brooklyn federal court of several charges in the case.

In January, a federal judge banned Shkreli for life from the pharmaceutical industry and ordered him to pay nearly $25 million in civil penalties for engaging in anticompetitive conduct to protect Vyera’s profits earned from Daraprim.

Vyera paid $40 million to plaintiffs in that same case, which included the Federal Trade Commission and seven states, among them New York and California.



Source

Nike stock soars 17% after CEO soothes investors, says recovery is on the horizon
Business

Nike stock soars 17% after CEO soothes investors, says recovery is on the horizon

Nike stock soared 17% on Friday after the company said the worst of its struggles are behind it, following a better than feared fiscal fourth-quarter earnings report.  Nike on Thursday reiterated it would take the biggest financial hit from its turnaround plan during the quarter, soothing investors who worried President Donald Trump’s tariff hikes on […]

Read More
Hemi V-8 engines and mechanical bull rides: Inside Stellantis’ plan to revive its Ram Trucks brand after yearslong sales declines
Business

Hemi V-8 engines and mechanical bull rides: Inside Stellantis’ plan to revive its Ram Trucks brand after yearslong sales declines

Stellantis’ Ram display is seen at the New York International Auto Show on April 16, 2025. Danielle DeVries | CNBC AUBURN HILLS, Mich. — Ram CEO Tim Kuniskis reemerged from a seven-month retirement late last year saying he “missed the fight” and admitting the Stellantis brand was getting smashed in the marketplace by its competition. […]

Read More
​Here’s how the luxury real estate market is splitting up
Business

​Here’s how the luxury real estate market is splitting up

View of luxury waterfront homes and boats along the intracoastal waterway near Jupiter Inlet in Jupiter, Florida in Palm Beach County Ryan Tishken | Istock | Getty Images A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future […]

Read More